Luspatercept for β-thalassemia: beyond red blood cell transfusions.
Ali T TaherMaria Domenica CappelliniPublished in: Expert opinion on biological therapy (2021)
The recent approval of luspatercept offers a new, long-term therapeutic option for adult patients with transfusion-dependent β-thalassemia to reduce red blood cell transfusion burden, anemia, and iron overload.